Please enable Javascript
Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Prostate Cancer
Localized
mHSPC/mCSPC
CRPC
RLT
Prostate Cancer Diagnostics
Prostate Cancer
Localized
mHSPC/mCSPC
CRPC
Advertisement
Renal Cell Carcinoma Knowledge Hubs
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Advertisement
Urothelial Carcinoma Knowledge Hubs
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Roundtable Discussions
Molecular Biomarkers and Risk Stratification in High-Risk Non-Muscle Invasive Bladder Cancer
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
December 16, 2024
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
Frontline vs Sequenced Therapies in BCG-Unresponsive Bladder Cancer: What's the Best Approach?
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
December 16, 2024
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
Combination Therapies in Bladder Cancer: Insights and Challenges
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
December 16, 2024
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
TAR-200 Monotherapy for NMIBC Durability and Dwell Time
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
December 16, 2024
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
December 16, 2024
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
Navigating the BCG Shortage: Gem/Doce and Clinical Trials for NMIBC
Roger Li, MD
Non-Muscle Invasive Urothelial Carcinoma
|
December 16, 2024
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
View Full Archive
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Editor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Editor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPH
Editor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhD
Editor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MD
Editor | Urologist at Swedish Health Services
David Ambinder, MD
Editor | Urology Resident at New York Medical College/Westchester Medical Center